CD79A and breast cancer: At present, IgA monoclonal antibodies targeting tumor cells such as breast cancer HER2 (human epidermal growth factor receptor 2) and B-cell lymphoma CD20 have shown a strong anti-tumor effect (Meyer et al., 2016).